The Field's Oldest Promise, Redeemed
Long before depression and PTSD claimed the renaissance's spotlight, addiction was the psychedelic compounds' original therapeutic claim. The first golden age's most-cited studies were alcoholism trials; Bill Wilson, AA's founder, spent his final years lobbying (unsuccessfully) for LSD-assisted work with alcoholics; and the modern renaissance's founding framing, before the marketing departments arrived, was substantially about addiction: the compounds' capacity to break the entrenched patterns of craving, to confront the user with the truth of their relationship to the substance, and to open the plasticity window in which new patterns can be built. The modern trials have now run that promise through the rigorous gauntlet for the two most consequential legal addictions on earth, alcohol and tobacco, with results that stand among the renaissance's most practically significant. This post is the addiction evidence: what the alcohol and tobacco trials found, why the mechanism fits addiction uniquely well, and where the frontier runs next.
The Alcohol Trials
The flagship result is the NYU-Johns Hopkins alcohol trial of the early 2020s, and its headline finding deserves the precision this series brings to every trial: in a randomized controlled design, participants receiving psilocybin-assisted therapy (two sessions, with the full preparation-integration apparatus) showed dramatically greater reductions in heavy drinking days than those receiving an active placebo (diphenhydramine, a Benadryl-class sedative chosen to make blinding less hopeless) plus the same therapy structure. The effect size was large: the psilocybin group's heavy-drinking days fell by roughly 80 percent across the follow-up period, with a substantial fraction achieving total abstinence, against meaningfully smaller reductions in the placebo-plus-therapy group. The trial's design is worth appreciating: the active placebo and the strong therapy structure in both arms were the field's answer to its own placebo problem, and the psilocybin advantage survived that rigor, which is exactly the kind of result the FDA's 2024 MDMA caution demanded more of.
The phenomenology, reported in the qualitative follow-ups, maps onto the mechanism: participants described the sessions as confronting them with the full truth of their drinking, its origins, its costs, and its future, in a way that dissolved the denial architecture rather than arguing with it, and the post-session weeks as carrying a diminished craving and a changed relationship with alcohol that persisted. The mechanism story, the default-mode disruption reaching the craving and habit circuitry, the plasticity window enabling new patterns, the mystical-type experience correlating with outcomes, applies here as cleanly as anywhere in the literature.
The Tobacco Trials
The tobacco evidence is older and smaller but arguably more striking per capita, because nicotine dependence is among the most treatment-resistant conditions in all of medicine: the best pharmacotherapies produce sustained abstinence in the low double digits, and most smokers who try to quit fail repeatedly. The Johns Hopkins smoking-cessation study of the mid-2010s, using the full mystical-experience framework (high-dose sessions aimed at the complete experience, with extensive preparation and integration), reported sustained abstinence rates around 60 to 80 percent at six- and twelve-month follow-ups in small samples, a number so far beyond the pharmacotherapy benchmarks that it attracted the field's attention even through the small-sample caveats. The trial's design strengths and limits both deserve naming: the intensive protocol (multiple high-dose sessions, expert therapists, strong expectancy effects in motivated volunteers) means the result is a proof of possibility rather than a scalable treatment estimate, but the durability at one year, with the standard biochemical verification, distinguishes it from every quit-smoking intervention's usual evaporation.
The mechanism finding of the tobacco work deserves special note: smoking-cessation outcomes correlated strongly with the degree of mystical-type experience achieved, a dose-response-in-meaning that this series' ego-dissolution and awe posts have documented across indications, and that the addiction context makes newly interpretable: the experience seems to give the quitting attempt a meaning-frame large enough to compete with the addiction's, which is the competition every cessation treatment has quietly been losing.
Why Addiction Fits the Mechanism Uniquely
The addiction-psychedelic fit deserves its own structural statement, because it differs from the depression fit in an instructive way. Depression's stuckness is a mood and self-narrative; addiction's stuckness is a behavior with a pharmacological engine, craving plus habit plus identity, and the engine runs on exactly the circuitry the compounds perturb: the reward system's entrenchment, the habit loops of the basal ganglia, the self-narrative of the default mode network. The compounds appear to act on all three levels at once: the mystical experience rewrites the identity layer (the smoker's self-concept as a smoker), the default-mode disruption loosens the narrative layer (the drinking as coping), and the plasticity window lets the behavioral work (which in addiction means the hard daily business of not using) establish new circuitry in the period when it is most establishable. This multi-level fit is why the addiction trials have produced some of the field's largest effects, and why the addiction applications, more than most, seem to require the full protocol apparatus rather than the compound alone.
The Frontier
The current addiction frontier runs in several directions. Opioid-use-disorder applications are the obvious and urgent extension, running into the same access and funding gaps this series' ibogaine and cluster-headache posts have documented. Process addictions (gambling, eating) are being explored on the same mechanistic logic. The poly-addiction reality, most addicts use multiple substances, is forcing the trials toward more ecologically valid populations. And the delivery question, how to make an intensive multi-session protocol with expert therapists reach a population that skews toward the unhoused and uninsured, is the field's sharpest version of its access problem: the interventions that work best are the ones least deliverable to the people who most need them, and closing that gap is the addiction-frontier's defining work.
The Bottom Line
Addiction was the compounds' first promise and is now among their best-evidenced: the alcohol trial's survival of the active-placebo gauntlet, the tobacco trial's durability beyond every cessation benchmark, and the mechanism's unique multi-level fit with the addiction architecture make this frontier one of the renaissance's most consequential. The work now is the unglamorous scaling: reaching the populations the protocols were not designed for, funding the trials the market will not fund, and building the delivery infrastructure that the evidence keeps demanding and the field keeps lacking. The promise is old. The proof is new. The delivery is the next decade.
